Marinomed Targets Growth After Restructuring

Marinomed Biotech AG has successfully restructured, paving the way for future growth and an expected operating profit in 2025. The Austrian company has shifted focus to its Marinosolv technology, enhancing drug solubility and bioavailability. This move follows the sale of its Carragelose business to Unither Pharmaceuticals, providing financial stability.

The emphasis is on Budesolv, a nasal corticosteroid for allergic rhinitis treatment. Utilizing Marinosolv, Budesolv significantly reduces required doses and provides rapid effect without harmful preservatives. Switzerland serves as the starting point for global market penetration, supported by advanced talks with Swissmedic.

Financial forecasts predict a profit of EUR 18.9 million in Q1 2025 post-restructuring. Marinomed's strategy aims to secure shareholder confidence through operational success and market expansion.